ChemoTech changes language for information disclosure

Scandinavian ChemoTech AB has decided to change language from Swedish to English for disclosure of information. The change will take place with immediate effect which means that the Company will only communicate financial reports and press releases in English from today, January 9, 2025. Certain information will still be published in Swedish due to current regulations.

The change of language to English is a consequence of the fact that the Company largely operates in markets outside of Sweden and is experiencing increased interest from international stakeholders such as customers and other partners.

We are also delighted to announce that we will shortly launch the Company’s new website.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.